Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 547 matches for

First phase completed a year earlier than typical industry timelines

Werribee-trial-scaled

OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.

Infinitopes expands seed financing to $35 Million to accelerate clinical development of precision cancer vaccine

Financing co-led by Octopus Ventures and new investor Amplify Bio. Company readies its first-in-human clinical trial of ITOP1, a precision cancer vaccine designed to prevent recurrence in oesophageal cancer.

Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies

Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara’s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara’s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.

U-Ploid Biotechnologies to present five scientific abstracts at Fertility 2026

U-Ploid Biotechnologies, a biotechnology company developing next-generation reproductive therapeutics to address age-related fertility decline, today announced that five scientific abstracts have been accepted for presentation at Fertility 2026 in Edinburgh. The presentations take place today, 8 January 2026.

Certis Belchim and Moa sign strategic collaboration deal

Netherlands-based company becomes Moa's third major commercial partner in 18 months.

Nucleome Therapeutics nominates first preclinical development candidate

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.

Oxford Cancer Analytics graduates from the BioEscalator

In 2022, Oxford Cancer Analytics was voted the company Most Likely to be a Unicorn at that year’s BioEscalator Pitch Battle. Fast forward three years, and the company is well along its growth trajectory. OXcan has graduated from our facility as a fast-scaling diagnostics company, leveraging advanced proteomics and machine learning to develop innovative tests for earlier and more accurate assessment of lung diseases.

BioEscalator Annual Review 2024/25 - People and partnerships driving better patient health

In 2024/25, the BioEscalator community achieved remarkable milestones through collaboration with individuals and organisations across the innovation ecosystem. Our annual review, titled "People and partnerships driving better patient health," highlights significant accomplishments and companies such as Oxford Cancer Analytics, with its global perspective. Working with the University of Oxford, alongside tenants and alumni, has been significant in advancing the bioscience industry. This year emphasises our commitment to embracing new ideas while making a meaningful impact.

BioEscalator Bulletin - Winter 2025

Stay informed with the latest BioEscalator updates, tenant and alumni news in the Winter 2025 edition of the BioEscalator Bulletin.

Akimbo Bio crosses the bridge from academia to industry as it joins the BioEscalator

The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.

Spectre Bio moves from computation to the lab as it joins the BioEscalator

The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.

Icosphere Biosciences appoints Dr John Beadle as Non-Executive Director

Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.

U-Ploid Biotechnologies wins Femtech competition award at the Carlos Simón Foundation for research in women’s health

U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.

Abbott to acquire Exact Sciences

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.

Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease

Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.

Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.

Oxford Cancer Analytics secures new space at Inventa to accelerate diagnostic innovation

Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.

PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule

The Composition of Matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.

Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell

Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics.

Enara Bio’s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies

Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX™ as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.

Load More

Similar stories